Photodynamic therapy for nonsubfoveal choroidal neovascularization in 100 eyes with pathologic myopia

Am J Ophthalmol. 2007 Jan;143(1):77-82. doi: 10.1016/j.ajo.2006.09.052. Epub 2006 Oct 25.

Abstract

Purpose: To evaluate the visual and anatomic outcome of photodynamic therapy (PDT) in eyes with nonsubfoveal choroidal neovascularization (CNV) associated with pathologic myopia (PM).

Design: Interventional, noncomparative cases series.

Methods: Ninety-seven patients (100 eyes) who were treated with PDT at three centers and followed up for three to 44 months (mean 16.5 months). Outcome measures were visual acuity, lesion size, and the occurrence of subfoveal invasion.

Results: Median baseline visual acuity was 20/40(-2) and ranged from 20/20 to 20/160(+2). On average, visual acuity was stable throughout follow-up after a modest increase of about 0.5 lines between three and six months. The probability of losing 3 or more lines was 10% to 15% during the second year. Lesion size (median: 710 microns) slightly decreased after the first PDT and tended to increase later, but not to a statistically significant extent compared with baseline. The probability of developing subfoveal CNV stabilized at 10% in the second year. The mean number of PDTs per individual was 2.9 in the first year and 0.6 in the second.

Conclusions: Visual and anatomic outcomes of PDT, in this large group of patients with nonsubfoveal myopic CNV and good visual acuity, suggest that it may halt the progression of the disease in most cases.

Publication types

  • Multicenter Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Choroidal Neovascularization / drug therapy*
  • Choroidal Neovascularization / etiology
  • Choroidal Neovascularization / physiopathology
  • Female
  • Fluorescein Angiography
  • Follow-Up Studies
  • Fovea Centralis
  • Humans
  • Male
  • Middle Aged
  • Myopia, Degenerative / complications*
  • Myopia, Degenerative / physiopathology
  • Photochemotherapy*
  • Photosensitizing Agents / therapeutic use*
  • Retrospective Studies
  • Visual Acuity / physiology

Substances

  • Photosensitizing Agents